Severe Acute Respiratory Syndrome Pipeline Analysis Report 2026

Report Coverage

The Severe Acute Respiratory Syndrome Pipeline Analysis Report by Expert Market Research gives comprehensive insights into severe acute respiratory syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acute respiratory syndrome. The Severe Acute Respiratory Syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Severe Acute Respiratory Syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Severe Acute Respiratory Syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to severe acute respiratory syndrome.

Read more about this report - Request a Free Sample

Severe Acute Respiratory Syndrome Pipeline Outlook

The Severe Acute Respiratory Syndrome (SARS) pipeline outlook focuses on developing effective preventive and therapeutic options for coronavirus infections, including SARS-CoV-2. In May 2025, the U.S. FDA approved Nuvaxovid, a protein-based, adjuvanted COVID-19 vaccine, for active immunisation, protecting adults, including high-risk populations. This approval underscores ongoing innovation in vaccine technology, rapid adaptation to emerging variants, and expanded prophylactic options.

SARS treatments typically include antiviral agents, monoclonal antibodies, and supportive care, while vaccines remain the primary strategy for prevention. The pipeline continues to advance with novel antivirals, immunomodulators, and next-generation vaccines addressing evolving SARS coronavirus challenges.

Severe Acute Respiratory Syndrome Epidemiology

Severe Acute Respiratory Syndrome (SARS) represents a significant class of respiratory illnesses caused by coronaviruses, with SARS-CoV-2 emerging as the most impactful in recent history. The global outbreak that began in 2020 led to an unprecedented rise in infections, peaking in early 2022 with tens of millions of weekly reported cases. Reported case numbers declined through 2023 and 2024 as surveillance strategies increasingly relied on indicators such as hospitalisations and mortality rather than widespread diagnostic testing.

By March 2025, WHO reported that during a 28‑day period (6 Jan–2 Feb 2025) over 147,000 new cases occurred globally, representing a 16% decrease, while about 4,500 deaths were recorded (a 28% increase). Weekly PCR test positivity ranged from ~7.3% at the start of the period to ~5.0% at the end, across 103 countries. Several variants, including the JN.1 variant of interest and multiple variants under monitoring, continued to circulate, highlighting ongoing transmission and genomic evolution.

Severe Acute Respiratory Syndrome – Pipeline Therapeutic Assessment

Severe Acute Respiratory Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total severe acute respiratory syndrome clinical trials. Phase II represents 44% of ichthyosis clinical trials, followed by Phase III (41%), with the remaining trials distributed across Phase I, Phase IV, and early-phase studies.

Severe Acute Respiratory Syndrome Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the severe acute respiratory syndrome pipeline analysis include small molecules, monoclonal antibodies, immunomodulators, and vaccine candidates. The severe acute respiratory syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for severe acute respiratory syndrome. In May 2025, the U.S. FDA approved mNEXSPIKE, an updated mRNA COVID‑19 vaccine specifically targeting emerging SARS-CoV-2 variants, enhancing protective coverage. This approval underscores continued innovation in vaccine technology, rapid response to viral evolution, and the expansion of prophylactic options. The pipeline continues to focus on broad-spectrum antivirals, immunomodulators, and next-generation vaccines to address unmet needs globally.

Severe Acute Respiratory Syndrome Clinical Trials – Key Players

The EMR report for the severe acute respiratory syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed severe acute respiratory syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in severe acute respiratory syndrome clinical trials:

• GeoVax, Inc.
• ModernaTX, Inc.
• Novavax
• BioNTech SE
• Pfizer
• Invivyd, Inc.
• Gilead Sciences
• AstraZeneca
• Roche
• Regeneron Pharmaceuticals

Severe Acute Respiratory Syndrome – Emerging Drugs Profile

Key Questions Answered in the Severe Acute Respiratory Syndrome Pipeline Insight Report

• Which companies/institutions are leading the severe acute respiratory syndrome drug development?
• Which company is leading the severe acute respiratory syndrome pipeline development activities?
• What is the current severe acute respiratory syndrome commercial assessment?
• What are the opportunities and challenges present in the severe acute respiratory syndrome pipeline landscape?
• What is the efficacy and safety profile of severe acute respiratory syndrome pipeline drugs?
• Which company is conducting major trials for severe acute respiratory syndrome drugs?
• Which companies/institutions are involved in severe acute respiratory syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in severe acute respiratory syndrome?

Reasons To Buy This Report

The Severe Acute Respiratory Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for severe acute respiratory syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into severe acute respiratory syndrome collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

COVID-19 Diagnostics Market

Acute Respiratory Syndrome Treatment Market

Acute Respiratory Distress Syndrome Market